Company Overview of Abdi Ibrahim Ilaç Sanayi ve Ticaret A.S.
Abdi Ibrahim Ilaç Sanayi ve Ticaret A.S. manufactures and markets pharmaceuticals for customers in Turkey and internationally. It offers antianemic, antibacterial/antiviral, gastrointestinal, nervous system, ophthalmic, and urogenital system drugs; vitamins and minerals; CANMAb, a biosimilar of trastuzumab used for the treatment of Her2+ breast cancer; and respiratory system, cardiovascular system, dermatologic, endocrine and metabolism, and NSAI and myorelaxant products. Abdi Ibrahim Ilaç Sanayi ve Ticaret A.S. was formerly known as Ibrahim Abdi Barut and changed its name to Abdi Ibrahim Ilaç Sanayi ve Ticaret A.S. in 1975. The company was founded in 1912 and is based in Istanbul, Turkey. I...
Eski Büyükdere Caddesi No: 4
Founded in 1912
Key Executives for Abdi Ibrahim Ilaç Sanayi ve Ticaret A.S.
Chief Executive Officer and Member of The Board of Directors
General Manager of Technical
Director of Corporate Communications
Compensation as of Fiscal Year 2017.
Abdi Ibrahim Ilaç Sanayi ve Ticaret A.S. Key Developments
Abdi Ibrahim Remede Pharma Obtains U.S. Food and Drug Administration Approval for Biosimilar Trastuzumab
Dec 23 17
Abdi Ibrahim Remede Pharma (AIRP) is Biocon's partner in Algeriafor the registration, marketing and pharmacovigilance monitoring of multiple Biotech Products. In 2016, AIRP launched the first Biosimilar of Trastuzumab (CANMAb®) in Algeria for the treatment of Her2+ breast cancer. Biocon's trastuzumab (filed and marketed through its US partner) is now approved by US FDA. Biocon's trastuzumab is the first FDA-approved biosimilar trastuzumab and the first biosimilar from Biocon´s portfolio to be approved in the U.S. It is only the second oncology biosimilar approved by US FDA. It received FDA approval after a 16-0 favorable vote by the Oncology Drugs Advisory Committee (ODAC), consisting of oncologists, pharmacologists, statisticians, manufacturing and other experts. In addition, the European Medicines Agency (EMA) has accepted the Marketing Authorization Application for Biocon's proposed biosimilar trastuzumab for review.
Abdi Ibrahim Seeks Acquisitions
Sep 6 16
Abdi Ibrahim Ilaç Sanayi ve Ticaret A.S. is seeking acquisitions. Nezih Barut, Chairman of Abdi Ibrahim, said, "We continue relentlessly our overseas investments, which stand at the heart of our growth targets. Our Kazakhstan factory started production in 2015. In 2017, Abdi Ibrahim Remede Pharma in Algeria will become operational, as our third manufacturing facility besides Turkey and Kazakhstan. In line with our 2020 goals, we have designated our five areas of growth as current products, new products, international markets operations, contract manufacturing services, and seizing merger and acquisition opportunities; and will continue to make swift progress in each of these areas."
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries